Adelina Yafasova

Adelina Yafasova

Auto-generated profile, based on publicly available information

Adelina Yafasova

Department of Cardiology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in JACC
Verified
Journal Article
Closed access
AYAdelina Yafasova
Adelina Yafasova
EFEmil L. Fosbøl
Emil L. Fosbøl
MSMorten Schou
Morten Schou
BBBo Baslund
Bo Baslund
MFMikkel Faurschou
Mikkel Faurschou
JBJawad H. Butt
Jawad H. Butt

1 August 2020 in JACC
Verified
Journal Article
Closed access
AYAdelina Yafasova
Adelina Yafasova
EFEmil L. Fosbøl
Emil L. Fosbøl
MSMorten Schou
Morten Schou
FGFinn Gustafsson
Finn Gustafsson
KRKasper Rossing
Kasper Rossing
JBJawad H. Butt
Jawad H. Butt

8 February 2022 in Circulation
Verified
Journal Article
Closed access
PDF file
AYAdelina Yafasova
Adelina Yafasova
JBJawad H. Butt
Jawad H. Butt
MEMarie B. Elming
Marie B. Elming
JNJens C. Nielsen
Jens C. Nielsen
JHJens Haarbo
Jens Haarbo
LKLars Valeur Köber
Lars Valeur Köber
Background: DANISH (The Danish Study to Assess the Efficacy of Implantable Cardioverter Defibrillators [ICDs] in Patients With Nonischemic Systolic Heart Failure on Mortality) found that primary-prevention ICD implantation was not associated with an overall survival benefit in patients with nonischemic systolic heart failure during a median follow-up of 5.6 years, although there was a beneficial effect on all-cause mortality in patients ≤70 years. This study presents an additional 4 years of follow-up data from DANISH. Methods: In DANISH, 556 patients with nonischemic systolic heart failure were randomized to receive an ICD and 560 to receive usual clinical care and followed until June 30, 2016. In this long-term follow-up study, patients were followed until May 18, 2020. Analyses were conducted for the overall population and according to age (≤70 and >70 years). Results: During a median follow-up of 9.5 years (25th–75th percentile, 7.9–10.9 years), 208/556 patients (37%) in the ICD group and 226/560 patients (40%) in the control group died. Compared with the control group, the ICD group did not have significantly lower all-cause mortality (hazard ratio [HR] 0.89, [95% CI, 0.74–1.08]; P = 0.24). In patients ≤70 years (n = 829), all-cause mortality was lower in the ICD group than the control group (117/389 [30%] versus 158/440 [36%]; HR, 0.78 [95% CI, 0.61–0.99]; P = 0.04), whereas in patients >70 years (n = 287), all-cause mortality was not significantly different between the ICD and control group (91/167 [54%] versus 68/120 [57%]; HR, 0.92 [95% CI, 0.67–1.28]; P = 0.75). Cardiovascular death showed similar trends (overall, 147/556 [26%] versus 164/560 [29%]; HR, 0.87 [95% CI, 0.70–1.09]; P = 0.20; ≤70 years, 87/389 [22%] versus 122/440 [28%]; HR, 0.75 [95% CI, 0.57–0.98]; P = 0.04; >70 years, 60/167 [36%] versus 42/120 [35%]; HR, 0.97 [95% CI, 0.65–1.45]; P = 0.91). The ICD group had a significantly lower incidence of sudden cardiovascular death in the overall population (35/556 [6%] versus 57/560 [10%]; HR, 0.60 [95% CI, 0.40–0.92]; P = 0.02) and in patients ≤70 years (19/389 [5%] versus 49/440 [11%]; HR, 0.42 [95% CI, 0.24–0.71]; P = 0.0008), but not in patients >70 years (16/167 [10%] versus 8/120 [7%]; HR, 1.34 [95% CI, 0.56–3.19]; P = 0.39). Conclusions: During a median follow-up of 9.5 years, ICD implantation did not provide an overall survival benefit in patients with nonischemic systolic heart failure. In patients ≤70 years, ICD implantation was associated with a lower incidence of all-cause mortality, cardiovascular death, and sudden cardiovascular death. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT00542945.

3 September 2021 in European Heart Journal
Verified
Journal Article
Closed access
JPJeppe Kofoed Petersen
Jeppe Kofoed Petersen
JBJawad Haider Butt
Jawad Haider Butt
AYAdelina Yafasova
Adelina Yafasova
CTChristian Torp-Pedersen
Christian Torp-Pedersen
RSRikke Sørensen
Rikke Sørensen
LØLauge Østergaard
Lauge Østergaard
Aims : The aim of this study was to examine contemporary data on the 1-year prognosis of patients surviving acute coronary syndrome (ACS) and concomitant first-time detected atrial fibrillation (AF). Methods and results: Using Danish nationwide registries, we identified all patients surviving a first-time admission with ACS from 2000 to 2018 and grouped them into (i) those without AF prior to or during ACS; (ii) those with a history of AF; and (iii) those with first-time detected AF during admission with ACS. With 1 year of follow-up, rates of ischaemic stroke, death, and bleeding were compared between study groups using multivariable adjusted Cox proportional hazards analysis. We included 161 266 ACS survivors: 135 878 (84.2%) without AF, 18 961 (11.8%) with history of AF, and 6427 (4.0%) with first-time detected AF at admission with ACS. Compared to those without AF, the adjusted 1-year rates of outcomes were as follows: ischaemic stroke [hazard ratio (HR) 1.38 (95% CI 1.22–1.56) for patients with history of AF and HR 1.67 (95% CI 1.38–2.01) for patients with first-time detected AF]; mortality [HR 1.25 (95% CI 1.21–1.31) for patients with history of AF and HR 1.52 (95% CI 1.43–1.62) for patients with first-time detected AF]; and bleeding [HR 1.22 (95% CI 1.14–1.30) for patients with history of AF and HR 1.28 (95% CI 1.15–1.43) for patients with first-time detected AF]. Conclusion : In patients with ACS, first-time detected AF appeared to be at least as strongly associated with the 1-year rates of ischaemic stroke, mortality, and bleeding as compared with patients with a history of AF.

1 May 2021 in Stroke
Verified
Journal Article
Closed access
PDF file
AYAdelina Yafasova
Adelina Yafasova
EFEmil Loldrup Fosbøl
Emil Loldrup Fosbøl
SJSøren Paaske Johnsen
Søren Paaske Johnsen
CKChristina Kruuse
Christina Kruuse
JPJeppe Kofoed Petersen
Jeppe Kofoed Petersen
JBJawad Haider Butt
Jawad Haider Butt
Background and Purpose: It is well-established that increasing treatment delay reduces the benefits of thrombolysis in patients with acute ischemic stroke. However, most studies focus on short-term outcomes. This study examined long-term outcomes according to time to thrombolysis in patients with first-time ischemic stroke. Methods: In this nationwide cohort study, all Danish patients with first-time ischemic stroke treated with intravenous thrombolysis between 2011 and 2017 and alive at discharge were identified through the Danish Stroke Registry. The association between time from symptom onset to thrombolysis and the long-term rate of the composite of death and recurrent ischemic stroke was examined using multivariable Cox regression and restricted cubic spline analysis. Results: The study population included 6252 patients with first-time ischemic stroke treated with thrombolysis (median age, 69 years [25th–75th percentile 60–78 years], 60% men). The median follow-up was 2.5 years (25th–75th percentile 1.2–4.1 years). The median time to thrombolysis was 138 minutes (25th–75th percentile 101–185 minutes), and the median National Institutes of Health Stroke Scale score at presentation was 5 (25th–75th percentile 3–10). The absolute 3-year risk of the composite outcome was 19.0% (95% CI, 16.4%–21.8%) in the 0 to 90 minute group, 23.3% (21.8%–24.9%) in the 91 to 180 minute group, and 23.8% (21.6%–26.1%) in the 181 to 270 minute group. Compared with thrombolysis within 90 minutes, time to thrombolysis >90 minutes was associated with a higher rate of the composite outcome (91–180 minute: adjusted hazard ratio, 1.25 [95% CI, 1.06–1.48]; 181–270 minutes: adjusted hazard ratio, 1.35 [95% CI, 1.12–1.61]). In restricted cubic spline analysis, the rate of the composite outcome increased with increasing time to thrombolysis and leveled off after 138 minutes. Conclusions: In this nationwide cohort of patients with ischemic stroke, the long-term rate of the composite of death and recurrent ischemic stroke increased with increasing time from symptom onset to initiation of thrombolysis.

27 October 2020 in Neurology
Verified
Journal Article
Closed access
PDF file
AYAdelina Yafasova
Adelina Yafasova
EFEmil Loldrup Fosbøl
Emil Loldrup Fosbøl
MCMia Nielsen Christiansen
Mia Nielsen Christiansen
NVNaja Emborg Vinding
Naja Emborg Vinding
CACharlotte Andersson
Charlotte Andersson
JBJawad Haider Butt
Jawad Haider Butt
Objective To examine whether the incidence, comorbidity, and mortality of first-time ischemic stroke changed in Denmark between 1996 and 2016 overall and according to age and sex using a nationwide cohort design. Methods In this cohort study, 224,617 individuals ≥18 years of age admitted with first-time ischemic stroke between 1996 and 2016 were identified through Danish nationwide registries. We calculated annual age-standardized incidence rates and absolute 30-day and 1-year mortality risks. Furthermore, we calculated annual incidence rate ratios using Poisson regression, odds ratios for 30-day mortality using logistic regression, and hazard ratios for 1-year mortality using Cox regression. Results The overall age-standardized incidence rates of ischemic stroke per 1,000 person-years increased from 1996 (2.70 [95% confidence interval [CI] 2.65–2.76]) to 2002 (3.25 [95% CI 3.20–3.31]) and then gradually decreased to below the initial level until 2016 (1.99 [95% CI 1.95–2.02]). Men had higher incidence rates than women in all age groups except 18 to 34 and ≥85 years. Absolute mortality risk decreased between 1996 and 2016 (30-day mortality from 17.1% to 7.6% and 1-year mortality from 30.9% to 17.3%). Women between 55 and 64 and ≥85 years of age had higher mortality than men. Similar trends were observed for all analyses after multivariable adjustment. The prevalence of atrial fibrillation, hypertension, diabetes mellitus, and use of lipid-lowering medication increased during the study period. Conclusions The age-standardized incidence of first-time hospitalization for ischemic stroke increased from 1996 to 2002 and then gradually decreased to below the initial level until 2016. Absolute 30-day and 1-year mortality risks decreased between 1996 and 2016. These findings correspond to increased stroke prevention awareness and introduction of new treatments during the study period.